Sanofi licenses immune disease drugs from startup Earendil [Yahoo! Finance]
Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases [Yahoo! Finance]
Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board [Yahoo! Finance]
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights [Yahoo! Finance]
Sanofi (NASDAQ: SNY) is now covered by analysts at BNP Paribas. They set an "outperform" rating and a $65.00 price target on the stock.